Johnson & Johnson’s Once-Daily Pill Eases Psoriatic Arthritis in Late-Stage Trial, Offering Hope of an Injection-Free Option

Johnson & Johnson has reported that its once-daily pill ICOTYDE eased the symptoms of psoriatic arthritis in a late-stage clinical trial, raising the prospect of the first oral peptide treatment for a disease that today is mostly managed with injections or infusions.

The company announced on Saturday, 7 November 2026, that the drug, known generically as icotrokinra, met the primary goal of the Phase 3 ICONIC-PsA 1 study, according to Reuters. Fifty-eight per cent of patients who took a 200-milligram tablet once a day achieved at least a 20 per cent improvement in joint symptoms after 16 weeks, compared with 41 per cent of those who received a placebo. The results were presented as a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2026 meeting.

The trial enrolled 552 adults with active psoriatic arthritis who had never previously received a biologic medicine, according to Johnson & Johnson. It was a randomised, double-blind, placebo-controlled study, the design regarded as the most rigorous way of testing whether a new treatment genuinely works.

The headline result was not the only encouraging signal. On the stricter measures of improvement used by rheumatologists, 29 per cent of patients on the drug reached a 50 per cent improvement in joint symptoms, against 16 per cent on placebo, while 13 per cent reached a 70 per cent improvement, against 5 per cent on placebo. The company described those secondary results as numerically higher rather than formally tested for statistical significance.

Skin symptoms, which matter deeply to patients because psoriatic arthritis attacks the skin as well as the joints, improved markedly too. Among patients with enough skin involvement to measure, 57 per cent of those taking the drug had clear or almost clear skin after 16 weeks, compared with 14 per cent of those on placebo. Thirty-seven per cent achieved a 90 per cent improvement in their psoriasis severity score, against 6 per cent on placebo. Both skin results were statistically significant, according to the company.

The benefits appeared to deepen with time. By week 24, response rates on the 200-milligram dose had risen to 69 per cent for the 20 per cent improvement measure, 40 per cent for the 50 per cent measure and 18 per cent for the 70 per cent measure. Among patients with qualifying skin involvement, 64 per cent had clear or almost clear skin by then, and 56 per cent had achieved a 90 per cent improvement in their psoriasis score. Patients in the placebo group had crossed over to receive the drug after week 16, so there was no placebo comparison at week 24.

Safety data through week 24 were consistent with the drug’s established profile, with no new safety signals identified, according to Johnson & Johnson. The company said the most common side effects seen with the medicine include headache, nausea, cough, fungal infection and tiredness, and that, like other medicines that act on the immune system, it can lower the body’s ability to fight infections.

ICOTYDE is not yet approved for psoriatic arthritis. It is currently approved in the United States for moderate-to-severe plaque psoriasis in adults and in children aged 12 and older who weigh at least 40 kilograms, a clearance granted by the Food and Drug Administration in March 2026. The new trial is the first Phase 3 test of the drug in psoriatic arthritis, and the company is expected to use the results to seek an expanded approval.

What psoriatic arthritis is, and why it is so hard to live with

Psoriatic arthritis is a chronic, immune-mediated inflammatory disease that attacks the joints and the skin. It causes pain, stiffness and swelling in and around the joints, along with the red, scaly patches of plaque psoriasis. It can also inflame the places where tendons and ligaments meet bone, a painful condition called enthesitis, and it can swell whole fingers and toes into the sausage-like shape doctors call dactylitis. Some patients develop inflammation of the spine as well.

The disease commonly appears between the ages of 30 and 50, although it can develop at any age, according to Johnson & Johnson. Nearly half of patients experience moderate fatigue and about a third suffer from severe fatigue. Comorbidities such as obesity, cardiovascular disease, anxiety and depression are often present alongside it, adding to the burden.

Psoriasis itself affects about 2 to 3 per cent of the world’s population, corresponding to more than 125 million people, and up to a third of them go on to develop psoriatic arthritis. According to Johnson & Johnson, nearly 30 per cent of people with plaque psoriasis develop the joint disease. The United States National Institute of Arthritis and Musculoskeletal and Skin Diseases puts the figure at approximately 30 per cent as well.

That scale explains why a new treatment matters. For many patients, the disease is not a single problem but a cluster of them: sore, swollen joints that make ordinary tasks difficult, skin lesions that are visible and stigmatising, exhaustion that does not lift with rest, and a higher risk of other serious conditions. Existing treatments can help, but many patients cycle through them without finding lasting control.

Treatment usually begins with anti-inflammatory painkillers and conventional disease-modifying drugs such as methotrexate. When those fail, doctors step up to targeted biologic medicines that block specific parts of the immune system. The most powerful of these are given by injection under the skin or by intravenous infusion in a clinic. For a lifelong disease, that routine becomes a burden in itself: needles, refrigeration, clinic visits, and the quiet dread that many people feel about self-injection.

There are oral options. Bristol Myers Squibb’s Sotyktu and Amgen’s Otezla are both pills, and they are already on the market. But the most effective targeted treatments for psoriatic arthritis have, until now, been the injectable biologics, including AbbVie’s Skyrizi and UCB’s Bimzelx, both of which block the same inflammatory pathway that icotrokinra targets. A pill that matches their effectiveness would change the daily reality of treatment for millions of people.

How the drug works

ICOTYDE is the first and only targeted oral peptide designed to block the interleukin-23 receptor, according to Johnson & Johnson. Interleukin-23, usually shortened to IL-23, is a signalling protein that acts as a master switch in the immune system. In people with psoriatic disease, excessive IL-23 signalling drives the activation of a type of immune cell known as T-helper 17 cells, which release a cascade of inflammatory chemicals that attack skin cells and joint tissue.

By binding directly to the IL-23 receptor, icotrokinra halts that inflammatory cascade at its source. The company says the drug binds to the receptor with single-digit picomolar affinity, a measure of how tightly a molecule grips its target, and has shown potent and precise inhibition of IL-23 signalling in human T cells in laboratory studies, although the clinical significance of that laboratory finding is not yet established.

What makes the drug unusual is its form. Peptides are short chains of amino acids, the building blocks of proteins, and they are normally destroyed by digestion, which is why peptide medicines are usually injected. Icotrokinra is an engineered peptide designed to survive the gut, be absorbed into the bloodstream and still find its target. If it works as intended, it offers the precision of a biologic in the convenience of a pill.

Patients take one tablet once a day, on waking, with water on an empty stomach, and wait at least 30 minutes before eating, according to the prescribing information. The tablet can also be dispersed in water for people who have difficulty swallowing.

The drug was jointly discovered by Johnson & Johnson and Protagonist Therapeutics under a licensing and collaboration agreement, and Johnson & Johnson holds the exclusive worldwide rights to develop and sell it.

What the trial showed in detail

The ICONIC-PsA 1 study, registered as NCT06878404, was designed to test once-daily oral icotrokinra against placebo in adults with active psoriatic arthritis who had never taken a biologic. Its primary endpoint was the proportion of patients achieving an ACR20 response at week 16.

ACR20 is a standard composite measure in rheumatology. It requires at least a 20 per cent improvement in both tender and swollen joint counts, plus at least a 20 per cent improvement in three of five other measures of disease activity, which include the patient’s and doctor’s overall assessments, pain scores, physical function and a blood marker of inflammation. ACR50 and ACR70 apply the same framework at 50 and 70 per cent improvement.

At week 16, 58 per cent of patients receiving the 200-milligram dose reached ACR20, compared with 41 per cent on placebo, a difference that met statistical significance with a p-value of 0.002, according to reports of the data. In plain terms, that means there is only a two-in-a-thousand chance that a gap of that size would have appeared by luck alone.

The skin results were, if anything, more striking. The Investigator’s Global Assessment, a five-point scale on which zero means clear skin and one means almost clear, showed 57 per cent of treated patients reaching clear or almost clear skin at week 16, against 14 per cent on placebo. On the Psoriasis Area and Severity Index, which grades how much of the body is covered by plaques and how red, thick and scaly they are, 37 per cent of treated patients achieved a 90 per cent improvement, against 6 per cent on placebo. Both differences were statistically significant at a nominal p-value of less than 0.001.

By week 24, the joint responses had continued to climb: 69 per cent ACR20, 40 per cent ACR50 and 18 per cent ACR70. Skin responses climbed too, with 64 per cent of patients with qualifying skin involvement reaching clear or almost clear skin and 56 per cent achieving a 90 per cent improvement in their severity score. Because the placebo group had switched to the drug after week 16, those later figures have no placebo comparison, and they should be read as evidence that the benefit is sustained and deepening rather than as a head-to-head result.

David Lee, Johnson & Johnson’s global immunology head, told Reuters that about 30 per cent of patients with psoriasis also have psoriatic arthritis, highlighting what he called a significant unmet need. “Many people living with psoriatic arthritis are still searching for treatments that can effectively address the full burden of their disease,” he said in the company’s announcement. “These new findings underscore the potential of ICOTYDE to meaningfully improve outcomes in psoriatic arthritis and add to the growing body of evidence across psoriatic disease.”

Dr Joseph F. Merola, a rheumatologist and dermatologist who leads the Psoriasis and Psoriatic Arthritis Multicenter Advancement Network, said the joint responses showed “the exciting potential for ICOTYDE, a targeted oral peptide therapy, to open an entirely new chapter in treating psoriatic arthritis with an oral option”. He added that effective management of the disease requires addressing both joint and skin disease, and that patients continue to need options that provide meaningful improvement across both. Johnson & Johnson notes that Dr Merola is a paid consultant for the company, although he was not compensated for media work on the announcement.

The wider trial programme

ICONIC-PsA 1 is one of two Phase 3 trials of the drug in psoriatic arthritis. The second, ICONIC-PsA 2, is testing it in patients who have and have not previously taken biologics, and has not yet reported results. That trial matters because it will show whether the drug also helps the harder-to-treat patients who have already failed one or more biologic medicines, the group in whom new options are most urgently needed.

The psoriatic arthritis readout came in the same week as positive results from the ICONIC-ASCEND study in plaque psoriasis, which met both of its co-primary endpoints at 16 weeks, according to reports. The psoriasis programme also includes the ICONIC-LEAD and ICONIC-TOTAL studies, and two head-to-head studies, ICONIC-ADVANCE 1 and 2, which compare the drug with both placebo and deucravacitinib, Bristol Myers Squibb’s Sotyktu, in adults with moderate-to-severe plaque psoriasis.

Johnson & Johnson is also studying the drug in moderately to severely active ulcerative colitis and Crohn’s disease, two inflammatory bowel conditions in which the IL-23 pathway is also implicated. The breadth of the programme reflects the company’s commercial hopes: Reuters reported that Wall Street analysts have tipped the drug as Johnson & Johnson’s next blockbuster, and that the company expects peak sales to top $5 billion across multiple indications.

That forecast is not only about psoriatic arthritis. It is about a single molecule that could be sold, at different doses and in different formulations, across psoriasis, psoriatic arthritis and inflammatory bowel disease, three large markets in which IL-23 blockade is already a proven approach. Whether the drug reaches that scale will depend on the results still to come, on pricing and on how regulators and insurers receive it.

Analysis: Why It Matters

A pill that could end the needle burden

The most immediate significance of this result is practical, not scientific. For a patient with psoriatic arthritis, the difference between an injection and a pill is the difference between a medical procedure and a morning routine. Injections must be stored cold, carried carefully when travelling, and administered on schedule, often with the help of a nurse or a family member. Infusions mean hours in a clinic. A once-daily tablet taken with a glass of water removes all of that. If the drug is approved for psoriatic arthritis, it will be the first oral treatment that blocks the IL-23 receptor, the pathway that the most effective injectable biologics target. That matters because adherence is one of the quietest problems in chronic disease: treatments only work when patients actually take them, and people are far more likely to keep taking a pill than to keep injecting themselves for decades. The trial’s skin results reinforce the point, since patients who see their skin clear are more likely to stay on treatment, and staying on treatment is what protects joints from irreversible damage.

The numbers are strong, but they need honest reading

Fifty-eight per cent against 41 per cent is a real and statistically significant result, but it deserves a careful look. The placebo response of 41 per cent is high, which is common in psoriatic arthritis trials, where the natural fluctuation of the disease, the attention patients receive in a trial, and the expectation of benefit all lift the placebo group. The gap between the two arms is 17 percentage points, which means roughly one extra patient in six benefits from the drug compared with placebo at 16 weeks. That is a meaningful effect, and it is in line with what other modern treatments achieve, but it is not a cure, and it is not a result that helps everyone. The deeper responses are more modest: fewer than a third of patients reached a 50 per cent improvement, and only about one in eight reached a 70 per cent improvement at 16 weeks. The week-24 figures look better, but they have no placebo comparison, so they cannot be used to prove how much of that improvement is the drug and how much is time, attention and the natural course of the disease. None of this diminishes the result; it simply sets the right expectation. This is a genuine advance for a substantial minority of patients, not a transformation for all of them, and the honest framing matters because patients make life-changing decisions on the basis of such numbers.

A crowded market is about to get more competitive

The psoriatic arthritis market is already crowded, and that is good news for patients. Injectable IL-23 blockers such as Skyrizi and Bimzelx are established and effective. Oral alternatives such as Sotyktu, which blocks a different enzyme called TYK2, and Otezla, which blocks an enzyme called PDE4, are already available as pills. Icotrokinra’s claim is that it combines the two advantages: the IL-23 mechanism of the best injectables with the convenience of a pill. If regulators agree, the competition will intensify, and competition in this market has historically meant better access, more choice and downward pressure on prices, even in a system as expensive as the American one. For Johnson & Johnson, the stakes are commercial as well as clinical. The company is building a franchise it expects to be worth more than $5 billion a year at its peak, and psoriatic arthritis is the second large indication after psoriasis itself. The head-to-head studies against Sotyktu in psoriasis will be watched closely, because they will show whether the new drug can beat an existing pill rather than merely beating a placebo, which is a much harder test and a much more useful one for doctors choosing between treatments.

The limits of the evidence so far

Three caveats should be kept in mind. First, the results come from a company announcement and a conference poster, not from a peer-reviewed paper in a medical journal. Peer review is the process by which independent experts examine the full data, check the analysis and probe for weaknesses, and it has not yet happened for this trial. The figures reported so far are the ones the company chose to highlight, and the full picture, including results for the 400-milligram dose and the active comparator arm, has not been published in detail. Second, every patient in ICONIC-PsA 1 had never taken a biologic. That is the easiest population in which to show a benefit, because their disease has not yet proved resistant to targeted treatment. The harder question, whether the drug helps people who have already failed one or more biologics, is being tested in ICONIC-PsA 2, and its answer is not yet known. Third, the safety picture is reassuring so far but short. Twenty-four weeks is a brief window for a drug that patients may take for decades, and the class-wide risks of immune suppression, including infections and tuberculosis, mean that long-term monitoring will be essential. None of these caveats is a reason to dismiss the result. They are reasons to treat it as the beginning of an evidence base rather than its conclusion.

What this means for patients waiting for better options

For the millions of people living with psoriatic arthritis, the practical message is one of cautious optimism. A new oral option that targets the IL-23 pathway is genuinely good news, and the fact that it improved both joints and skin in the same trial is particularly welcome, because the disease attacks both and patients experience it as one condition, not two. But the drug is not approved for psoriatic arthritis yet, and approval will take time: a regulatory submission, a review that typically lasts many months, and then negotiations over price and reimbursement in each country. Patients should also remember that the trial population was carefully selected, and that real-world results are often less impressive than trial results, because real patients are older, sicker and more complicated than trial volunteers. The best advice for anyone living with the disease remains unchanged: talk to a rheumatologist about the options that exist today, keep skin and joints monitored together, and treat new trial results as a reason for hope rather than a reason to stop a treatment that is currently working. The promise of this pill is real, but it is a promise for the near future, not for tomorrow morning.

What to Watch Next

1. The regulatory filing: whether Johnson & Johnson submits the psoriatic arthritis data to the Food and Drug Administration and to regulators in Europe and other regions, and how quickly those agencies move. A filing in early 2027 would put a decision in late 2027 or 2028.
2. The ICONIC-PsA 2 results: the second Phase 3 trial, in patients who have previously taken biologics, will show whether the drug works in the harder-to-treat population where new options are most needed.
3. Peer-reviewed publication: full publication of the ICONIC-PsA 1 data in a medical journal, including the 400-milligram dose results and the active comparator arm, will allow independent experts to judge the evidence in full.
4. The head-to-head psoriasis data: results from the ICONIC-ADVANCE studies, which compare icotrokinra directly with Sotyktu, will show whether the new pill beats an existing oral rival rather than only a placebo.
5. Price and access: the drug’s list price for psoriatic arthritis, and whether insurers and health systems cover it, will decide whether the benefit reaches ordinary patients or remains limited to those who can afford it.

Sources

• Reuters — J&J’s once-daily pill eases psoriatic arthritis symptoms in late-stage trial (7 November 2026)
• Johnson & Johnson — ICOTYDE (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity (7 November 2026)
• ClinicalTrials.gov — ICONIC-PsA 1 trial record (NCT06878404)
• Morningstar / PR Newswire — Johnson & Johnson announces ICOTYDE Phase 3 psoriatic arthritis results (7 November 2026)
• Health and Family — Once-daily oral drug shows promise for psoriatic arthritis, Phase 3 trial finds (8 November 2026)
• MLQ.ai — J&J’s Icotyde pill meets main goal in first Phase 3 psoriatic arthritis trial (8 November 2026)